Your Article Summary
Reversal of refractory septic shock with drotrecogin alpha (activated)
Intensive Care Medicine, 07/01/09
Vieillard-Baron A et al. - The objective of this study was to investigate whether early administration of drotrecogin alpha (activated) (DrotAA) to this selected subgroup of septic patients at extremely high risk of death would significantly improve prognosis. DrotAA therapy was associated with unexpectedly high 28-day survival in patients with "refractory" septic shock.
Related Articles
Standardized order sets for the treatment of severe sepsis and septic shock
Expert Review of Anti-infective Therapy, 11/12/09
Relevance Score: 69%
An explorative study on quality of life and psychological and cognitive function in pediatric survivors of septic shock
Pediatric Critical Care, 11/10/09
Relevance Score: 69%
Corticosteroids for severe sepsis and septic shock
Intensivmedizin und Notfallmedizin, 11/06/09
Relevance Score: 69%
Is pituitary failure the real therapeutic target in septic shock
Medical Hypotheses, 11/04/09
Relevance Score: 69%
Beta-2-Adrenergic Receptor Gene Polymorphism is Associated with Mortality in Septic Shock
American Journal of Respiratory and Critical Care Medicine, 10/27/09
Relevance Score: 68%
Today in Critical Care...keeping you current
Receive free subspecialty "5-minute updates" via email
H1N1 influenza A virus-associated acute lung injury: response to combination oseltamivir and prolonged corticosteroid treatment
Intensive Care Medicine, 12/07/09
Rehabilitation therapy and outcomes in acute respiratory failure: An observational pilot project
Journal of Critical Care, 12/04/09
How accurately do we measure blood glucose levels in intensive care unit (ICU) patients
Best Practice & Research - Clinical Anaesthesiology, 12/04/09

See Latest Articles